Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2006-02-14
2006-02-14
Nickol, Gary B. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S195110, C424S178100, C424S182100
Reexamination Certificate
active
06998125
ABSTRACT:
The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a cytotoxic T-lymphocyte inducing composition and at least one agent which is capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors, separately or in combination.
REFERENCES:
patent: 5514670 (1996-05-01), Friedman et al.
patent: 5585103 (1996-12-01), Raychaudhuri et al.
patent: 5695770 (1997-12-01), Raychaudhuri et al.
patent: 5709860 (1998-01-01), Raychaudhuri et al.
patent: 5932212 (1999-08-01), Khalaf
patent: 6197311 (2001-03-01), Raychaudhuri et al.
patent: 2002/0004052 (2002-01-01), Berd et al.
patent: WO94/09815 (1994-05-01), None
patent: WO 9409815 (1994-05-01), None
Wojtowicz-Praga et al. (Jnl. Immunology. May 1996, vol. 19. No. 3, pp. 169-175).
Arteaga et al. (J.Clin.Invest., Dec. 1993, vol. 92, pp. 2569-2576).
Hoefer et al. (Cancer Immunol. Immunother, 1995, vol. 41, pp. 302-308).
Matar et al. (Eur. J. Cancer, May 2000, vol. 36 No. 8, pp. 1060-1066).
Berd et al. (Cancer Research, vol. 46, May 1986, pp. 2572-2577).
Jianyin, L et al., May 1997, “Clinical Applications and Prospects of the Transforming Growth Factor B” Junshi Yixue Kexueyuan Yuankan Huagong, vol. 21, No. 2, pp. 135-139 (translated by FLS, Inc.).
Dybedal et al., “Transforming Growth Factor β (TGF-β), A Potent Inhibitor of Erythropoiesis: Neutralizing TGF-β Antibodies Show Erythropoietin as a Potent Stimulator of Murine Burst-Forming Unti Erythroid Colony Formation in the Absence of a Burst-Promoting Activity”,Blood,86(3): 949-957 (1995).
Sitnicka et al., “Transforming Growth Factor β1Directly and Reversibly Inhibits the Initial Cell Divisions of Long-Term Repopulating Hematopoietic Stem Cells”,Blood,88(1):82-88 (1996).
Jacobsen et al., “Transforming Growth Factor-β Potently Inhibits the Viability-Promoting Activity of Stem Cell Factor and Other Cytokines and Induces Apoptosis of Primitive Murine Hematopoietic Progenitor Cells”,Blood,86(8):2957-2966 (1995).
Clarke et al., “Lisofylline Inhibits Transforming Growth Factor β Release and Enhances Trilineage Hematopoietic Recovery after 5-Fluorouracil Treatment in Mice”,Cancer Research,56:105-112 (1996).
Kopp et al., “Transforming Growth Factor β2 (TGF-β2) Levels in Plasma of Patients with Metastatic Breat Cancer Treated with Tamoxifen1”,Cancer Research,55:4512-4515 (1995).
Sansilvestri et al., “Early CD34highCells Can Be Separated Into KIThighCells in Which Transforming Growth Factor-β (TGF-β) Downmodulates c-kitand KITlowCells in Which Anti-TFG-β Upmodulates c-kit”,Blood,86(5):1729-1735 (1995).
Jianyin, L et al., “Clinical application and potential of TGFβ,” Beijing Institute of Basic Medical Sciences, May 1997, pp. 135-140.
Hallinan et al., “Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs,”J Med Chem.,1996, 39:609-613.
Oka et al., “PGE2 receptor subtype EP1 antagonist may inhibit central interleukin-1β-induced fever in rats,”The American Physiological Society,1998, R1762-1765.
Isaac et al., “Successful treatment of established rat prostate cancer by transforming growth factor-B1 antisense transfected tumor vaccine,”J of Urology,197, 157:270.
Murphy et al., “Differential effects of growth hormone and prolactin on murine T cell development and function,”J Exp Med.,1993, 178:231-6.
Richards et al., “Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas,”Cell Immunol.,1998, 184:85-91.
Francis R. Carbone and Michael J. Bevan, “Class I-Restricted Processing and Presentation of Exogenous Cell-Associated with Antigen In Vivo,” Feb. 1990, 171:377-387.
Hidemi Takahashi, Toshiyuki Takeshita, Bror Morein, Scott Putney, Ronald N. Germain and Jay A. Berzofsky, “Induction of CD8+Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs”Nature,Apr. 26, 1990, 344:873-875.
Mark W. Moore, Francis R. Carbone, and Michael J. Bevan, “Introduction of Soluble Protein into the Class I Pathway of Antigen Processing and Presentation”Cell,Sep. 9, 1988, 54:777-785.
Brown et al., Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol. Jun 2004;125(6):743-8. Abstract only.
Comerci et al., Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer. Mar 15, 1996;77(6):1107-14. Abstract only.
De Wever et al.,Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-{beta} or wounding. J Cell Sci. Oct 15, 2004;117(Pt 20):4691-4703. Epub Aug. 25, 2004. Abstract only.
Hasegawa et al., Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. Mar 1, 2001;91(5):964-71. Abstract only.
Lee et al., Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line. Int J Cancer. Nov 15, 2001;94(4):500-7. Abstact.
Matsunaga et al., Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta. Ann Hematol. May 2004;83(5):322-5. Epub Nov 11, 2003. Abstractonly.
Medrano et al., Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene. May 19, 2003;22(20):3123-9. Abstract only.
Mitani, Molecurlar mechanisms of leukemogenesis by AML1/EVI-1. Oncogene. May 24, 2004;23(24):4263-9. Abstract only.
Mitropoulos et al., Expression of transforming growth factor beta in renal cell carcinoma and matched no-involved renal tissue. Urol Res. Sep 7, 2004 [Epub ahead of print]. Abstract only.
Matar et al., Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol. Feb 2001;1(2):307-19. Abstract only.
Piestrzeniewicz-Ulanska et al., Expression and intracellular localization of Smad proteins in human endometrial cancer. Oncol Rep. Sep-Oct 2003;10(5):1539-44. Abstract only.
Sacco et al., Transforming growth factor betal and soluble Fas serum levels in hepatocellular carcinoma. Cytokine. Jun 2000;12(6):811-4. Abstract only.
Schiemann et al. Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor. Cancer Detect Prev. 2004;28(1):57-64. Abstract only.
Seoane et al., Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. Apr 16, 2004;117(2):211-23. Abstract only.
Shariat et al., Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. Jun 1, 2001;19(11):2856-64. Abstract only.
Shariat et al., Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. Dec 15, 2001;92(12):2985-92. Abstract only.
Sheen-Chen et al., Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg. Aug 2001;136(8):937-40. Abstract.
Subramanian et al. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4
Braslawsky Gary R.
Hanna Nabil
Hariharan Kandasamy
Biogen IDEC Inc.
Nickol Gary B.
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Synergistic composition and methods for treating neoplastic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic composition and methods for treating neoplastic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic composition and methods for treating neoplastic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3630962